ESTRING

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ESTRING (ESTRING).

How it works

Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene expression and subsequent physiological effects including proliferation and differentiation of reproductive tissues, maintenance of bone density, and regulation of lipid metabolism.

What the body does with it

Metabolism	Estradiol is metabolized primarily in the liver via oxidation (cytochrome P450 1A2, 3A4, 1A1, 1B1) and conjugation (glucuronidation and sulfation).
Excretion	Renal: approximately 90% as glucuronide and sulfate conjugates; fecal: approximately 10% as conjugates; enterohepatic recirculation occurs.
Half-life	Terminal elimination half-life is approximately 13-20 hours; clinical context: provides sustained estradiol levels for local estrogenic effects with minimal systemic accumulation.
Protein binding	Estradiol is approximately 98% bound to plasma proteins, primarily to sex hormone-binding globulin (SHBG) and albumin.
Volume of Distribution	Vd is approximately 1.2 L/kg; indicates extensive distribution into tissues, including estrogen-responsive organs.
Bioavailability	Vaginal: local bioavailability is high, with systemic absorption producing estradiol levels similar to early follicular phase; systemic bioavailability relative to oral estradiol is lower due to first-pass effect avoidance but variable (approximately 10-20% of an oral dose).
Onset of Action	Vaginal: local effects on urogenital epithelium observed within 2-4 weeks of continuous use.
Duration of Action	Vaginal: sustained local effects for up to 90 days per ring; ring is replaced every 3 months to maintain efficacy.

Classification & Brands

Dosing & administration

One vaginal ring (2 mg estradiol) inserted into the upper third of the vagina every 90 days.

Dosage form	INSERT, EXTENDED RELEASE
Renal impairment	No specific dosage adjustment required; manufacturer does not provide GFR-based guidelines.
Liver impairment	Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in mild to moderate impairment (Child-Pugh A or B) and consider dose reduction.
Pediatric use	Not indicated for use in pediatric patients.
Geriatric use	Use lowest effective dose; monitor for endometrial cancer, cardiovascular events, and dementia risk; same dosing schedule as adults.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ESTRING (ESTRING).

Breastfeeding	Estradiol is excreted in human milk; M/P ratio unknown. May reduce milk production and quality. Use during breastfeeding is not recommended. If used, monitor infant for potential estrogenic effects.
Teratogenic Risk	Estradiol is contraindicated in pregnancy. Use during first trimester is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure may cause urogenital abnormalities and subsequent reproductive tract anomalies in offspring. Estrogens should not be used during pregnancy.

Warnings & precautions

■ FDA Black Box Warning

Estrogen-alone therapy: Increased risk of endometrial cancer in women with a uterus. Use progestin if uterus is intact. Not for prevention of cardiovascular disease or dementia.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Undiagnosed abnormal genital bleeding","Known or suspected pregnancy","Breast cancer (known, suspected, or history of)","Estrogen-dependent neoplasia","Active DVT, PE, or history of these conditions","Active arterial thromboembolic disease (e.g., stroke, MI) or history of these conditions","Known anaphylactic reaction or angioedema to estradiol","Known liver impairment or disease","Known thrombophilic disorders (e.g., protein C, protein S, or antithrombin deficiency)"]

Clinical Precautions

Precautions

["Endometrial cancer","Cardiovascular disorders","Dementia","Gallbladder disease","Hypercalcemia","Retinal vascular thrombosis","Fluid retention","Hypothyroidism","Angioedema","Exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ESTRING

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ESTRING (ESTRING).

How it works

What the body does with it

Metabolism	Estradiol is metabolized primarily in the liver via oxidation (cytochrome P450 1A2, 3A4, 1A1, 1B1) and conjugation (glucuronidation and sulfation).
Excretion	Renal: approximately 90% as glucuronide and sulfate conjugates; fecal: approximately 10% as conjugates; enterohepatic recirculation occurs.
Half-life	Terminal elimination half-life is approximately 13-20 hours; clinical context: provides sustained estradiol levels for local estrogenic effects with minimal systemic accumulation.
Protein binding	Estradiol is approximately 98% bound to plasma proteins, primarily to sex hormone-binding globulin (SHBG) and albumin.
Volume of Distribution	Vd is approximately 1.2 L/kg; indicates extensive distribution into tissues, including estrogen-responsive organs.
Bioavailability	Vaginal: local bioavailability is high, with systemic absorption producing estradiol levels similar to early follicular phase; systemic bioavailability relative to oral estradiol is lower due to first-pass effect avoidance but variable (approximately 10-20% of an oral dose).
Onset of Action	Vaginal: local effects on urogenital epithelium observed within 2-4 weeks of continuous use.
Duration of Action	Vaginal: sustained local effects for up to 90 days per ring; ring is replaced every 3 months to maintain efficacy.

Classification & Brands

Dosing & administration

One vaginal ring (2 mg estradiol) inserted into the upper third of the vagina every 90 days.

Dosage form	INSERT, EXTENDED RELEASE
Renal impairment	No specific dosage adjustment required; manufacturer does not provide GFR-based guidelines.
Liver impairment	Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in mild to moderate impairment (Child-Pugh A or B) and consider dose reduction.
Pediatric use	Not indicated for use in pediatric patients.
Geriatric use	Use lowest effective dose; monitor for endometrial cancer, cardiovascular events, and dementia risk; same dosing schedule as adults.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ESTRING (ESTRING).

Breastfeeding	Estradiol is excreted in human milk; M/P ratio unknown. May reduce milk production and quality. Use during breastfeeding is not recommended. If used, monitor infant for potential estrogenic effects.
Teratogenic Risk	Estradiol is contraindicated in pregnancy. Use during first trimester is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure may cause urogenital abnormalities and subsequent reproductive tract anomalies in offspring. Estrogens should not be used during pregnancy.

Warnings & precautions

■ FDA Black Box Warning

Estrogen-alone therapy: Increased risk of endometrial cancer in women with a uterus. Use progestin if uterus is intact. Not for prevention of cardiovascular disease or dementia.